Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.

The pharmacogenomics journal - 1 Feb 2011

Glimelius B, Garmo H, Berglund A, Fredriksson L A, Berglund M, Kohnke H, Byström P, Sørbye H, Wadelius M

Abstract excerpt

Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer. Irinotecan's active metabolite is inactivated by UDP-glucuronosyltransferase 1A1 (UGT1A1), which is deficient in Gilbert's syndrome. Irinotecan and metabolites are transported by P-glycoprotein, encoded by ABCB1. 5-FU targets folate metabolism through inhibition of thymidylate synthase (TYMS). Methylenetetrahydrofolate reductase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Fluorouracil

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neutropenia

Share to Thymidylate Synthase

Source

Open in PubMed Open full text

Identifiers

PMID: 20177420
DOI: 10.1038/tpj.2010.10
PMCID: PMC3036798

Genes

ABCB1
MTHFR
TYMS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.PMID 20177420Read ↗

UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.Semantic proximity Read ↗

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.Semantic proximity Read ↗

Prediction of severe toxicity in adult patients under treatment with 5-fluorouracil: a prospective cohort study.Semantic proximity Read ↗

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.Semantic proximity Read ↗

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS TrialSemantic proximity Read ↗

Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.Semantic proximity Read ↗

Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.Semantic proximity Read ↗

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.Semantic proximity Read ↗

UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.Semantic proximity Read ↗

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.Semantic proximity Read ↗

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.Semantic proximity Read ↗

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.